Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYM021 + SYM022
- Development stage
- Phase 1
- Lead developer
- Symphogen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SYM021 + SYM022 is a combination of two investigational monoclonal antibodies, SYM021 (an anti-PD-1 antibody) and SYM022 (an anti-LAG-3 antibody), designed to enhance antitumor immune responses by simultaneously blocking the PD-1 and LAG-3 immune checkpoints. Both antibodies are IgG proteins engineered to reduce immune resistance in advanced solid tumors or lymphomas by activating T cell-mediated immune responses. The combination has been evaluated in early-phase clinical trials for its safety, tolerability, and preliminary efficacy primarily in solid tumors such as biliary tract carcinoma and esophageal squamous cell carcinoma. The drugs are intravenously administered and are developed by Symphogen[1][2][5].
02
Targets
LAG3 (Lymphocyte activation Gene-3 protein)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on SYM021 + SYM022.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYM021 + SYM022.